1. Dual-targeted nanoparticulate drug delivery systems for enhancing triple-negative breast cancer treatment.
- Author
-
Zheng S, Li M, Xu W, Zhang J, Li G, Xiao H, Liu X, Shi J, Xia F, Tian C, and Kamei KI
- Subjects
- Animals, Humans, Female, Cell Line, Tumor, Prodrugs administration & dosage, Prodrugs therapeutic use, Linoleic Acid chemistry, Linoleic Acid administration & dosage, Triazoles administration & dosage, Triazoles pharmacology, Triazoles chemistry, DNA Damage drug effects, Antineoplastic Agents administration & dosage, Antineoplastic Agents therapeutic use, Antineoplastic Agents pharmacology, Mice, Nude, Mice, Cell Cycle Proteins metabolism, Transcription Factors metabolism, Topoisomerase I Inhibitors administration & dosage, Bromodomain Containing Proteins, Azepines, Triple Negative Breast Neoplasms drug therapy, Nanoparticles administration & dosage, Nanoparticles chemistry, Acrolein analogs & derivatives, Acrolein administration & dosage, Acrolein chemistry, Drug Delivery Systems, Camptothecin analogs & derivatives, Camptothecin administration & dosage, Camptothecin therapeutic use, Camptothecin pharmacology
- Abstract
The efficacy of DNA-damaging agents, such as the topoisomerase I inhibitor SN38, is often compromised by the robust DNA repair mechanisms in tumor cells, notably homologous recombination (HR) repair. Addressing this challenge, we introduce a novel nano-strategy utilizing binary tumor-killing mechanisms to enhance the therapeutic impact of DNA damage and mitochondrial dysfunction in cancer treatment. Our approach employs a synergistic drug pair comprising SN38 and the BET inhibitor JQ-1. We synthesized two prodrugs by conjugating linoleic acid (LA) to SN38 and JQ-1 via a cinnamaldehyde thioacetal (CT) bond, facilitating co-delivery. These prodrugs co-assemble into a nanostructure, referred to as SJNP, in an optimal synergistic ratio. SJNP was validated for its efficacy at both the cellular and tissue levels, where it primarily disrupts the transcription factor protein BRD4. This disruption leads to downregulation of BRCA1 and RAD51, impairing the HR process and exacerbating DNA damage. Additionally, SJNP releases cinnamaldehyde (CA) upon CT linkage cleavage, elevating intracellular ROS levels in a self-amplifying manner and inducing ROS-mediated mitochondrial dysfunction. Our results indicate that SJNP effectively targets murine triple-negative breast cancer (TNBC) with minimal adverse toxicity, showcasing its potential as a formidable opponent in the fight against cancer., Competing Interests: Declaration of competing interest The authors declare that they have no competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024. Published by Elsevier B.V.)
- Published
- 2024
- Full Text
- View/download PDF